Physician profile
Augustine C Romano
NPI 1255486353
$24,701.93
in general payments reported to CMS, 2019-2025
74 companies · $4,129 in 2025
The $4,129 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,069 · 2020: $2,663 · 2021: $3,830 · 2022: $4,317 · 2023: $3,406 · 2024: $3,287 · 2025: $4,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21.28 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,781.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21.28 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,284.49 | 2021-2025 | Botox, Ubrelvy, Vraylar |
| Ucb, INC. | $1,688.39 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Biogen, INC. | $1,418.53 | 2019-2025 | Vumerity, Plegridy, Tysabri |
| Teva Pharmaceuticals USA, INC. | $1,261.49 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Lundbeck LLC | $1,139.96 | 2020-2025 | Vyepti, Rexulti |
| Allergan, INC. | $1,094.53 | 2019-2022 | |
| Sk Life Science, INC. | $996.52 | 2020-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $934.21 | 2019-2025 | |
| Amgen INC. | $930.89 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $822.58 | 2019-2022 | |
| Lilly USA, LLC | $809.45 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Amneal Pharmaceuticals LLC | $710.33 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Pfizer INC. | $703.09 | 2019-2025 | |
| Neurelis, INC. | $521.83 | 2022-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $500.23 | 2019-2025 | Nuplazid |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Romano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.